Oncology Supportive Care · LP-165
Folinic acid Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-165Oncology Supportive Care
- Generic identity
- Folinic acidTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-165
- Generic ingredient
- Folinic acid
- Dosage form
- Tablet
- Proposed strength
- 5 mg; 15 mg
- Proposed pack
- Blister/bottle
- Portfolio category
- Oncology Supportive Care
About Folinic acid
Folinic acid, commonly supplied as calcium folinate and called leucovorin in some references, is a reduced folate medicine. It has specific roles in modifying the effects of certain antifolate or cancer medicines. It is pharmacologically and clinically distinct from routine folic acid supplementation. Selection depends on the exact protocol, chemical form and route, rather than the similar spelling of folate-related ingredient names.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
In specialist care, folinic acid can be used to protect healthy cells in defined methotrexate-related situations or to modify fluorouracil treatment effects. Those contexts have different clinical objectives and must not be combined into a general instruction. Laboratory results, timing relative to other therapy and renal function can be critical. This catalogue does not provide chemotherapy, rescue or overdose regimens and does not establish their authorization for a Luang Pharma product.
Important safety considerations
Allergic reactions can occur. When combined with fluorouracil, folinic acid can intensify clinically important toxicity, including gastrointestinal and blood-cell effects. It is not appropriate as sole treatment for vitamin B12-deficiency anaemia because neurological injury can continue. Antiseizure medicines can require interaction review. Incorrect timing, route or product selection in a specialist protocol can be serious; all details must be verified by the responsible clinical and pharmacy team.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
This record concerns oral folinic-acid tablets. Confirm whether the labelled strength is expressed as folinic acid or a specific salt such as calcium folinate/leucovorin. Injectable folinate presentations and levofolinate products require separate identity, route and equivalence evidence and are not defined by this tablet record.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Review the exact specialist protocol, companion medicines, laboratory monitoring and formulation. Independently verify route and chemical identity; the catalogue is not a rescue-treatment instruction.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Folinic acid
- Dosage form / presentation
- Tablet
- Catalogue strength
- 5 mg; 15 mg
- Catalogue pack
- Blister/bottle
- Portfolio category
- Oncology Supportive Care
Layer 02
Unresolved product-specific fields
- P026 editorial correction: the inherited LP-178 injectable-vial note was removed. LP-165 is a folinic-acid tablet record.
- The catalogue does not establish whether strength is expressed as folinic acid, calcium folinate/leucovorin or another salt basis. Do not infer equivalence to injectable folinate or levofolinate products.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Leucovorin (folinic acid)government-hosted medicine monograph
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled tablet specification confirming folinic-acid chemical/salt form and the basis on which 5 mg and 15 mg strengths are expressed.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-165, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-165.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.